Ask AI
See Activity Collection
ProCE Banner Activity

From Smolder to Strategy: Optimizing Early Treatment Decisions in High-Risk SMM and NDMM

Slideset

Downloadable slides featuring evidence for the need for accurate risk stratification, evidence for early intervention, and how to decide between treatment and observation in an individualized manner for patients with high-risk smoldering MM, as well as the optimal approaches for the selection of frontline therapy for patients who are newly diagnosed with active MM requiring treatment. Slides also include a synthesized version of the evolving treatment landscape, recommended guidelines, and ongoing clinical trials for patients with high-risk smoldering MM and those with newly diagnosed active MM.

Released: October 22, 2026

Begin Activity

Share

Faculty

Natalie S. Callander

Natalie S. Callander, MD

Professor of Medicine
Director, Myeloma Clinical and Cellular Therapy Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from Johnson & Johnson and Sanofi Genzyme.

Johnson & Johnson

Sanofi Genzyme

Target Audience

This educational activity is intended for hematologists, oncologists, advanced practice providers, nurses, pharmacists, and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply risk stratification models, diagnostic criteria, and guideline recommendations to identify appropriate patients for early intervention in high-risk SMM

  • Integrate practical treatment delivery considerations, including intravenous vs subcutaneous antibody administration, supportive care requirements, and monitoring protocols, to align therapy selection with patient needs

  • Recall emerging data on novel agents and combination strategies under investigation and appropriately identify patients who may benefit from referral for clinical trial participation

  • Individualize frontline treatment strategies for patients with NDMM by integrating emerging clinical evidence, guidelines, cytogenetic risk, comorbidities, transplant eligibility, functional status, and patient preferences to optimize short-term and long-term outcomes